EGFR and non-small cell lung carcinoma: Kotake et al. also showed that interstitial lung disease (ILD) was seen in 21 % (4/19) of patients with the EGFR-T790M mutation-positive advanced NSCLC who received osimertinib shortly after prior nivolumab therapy [86].